Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.
Judith TrotmanChristian BuskeAlessandra TedeschiJeffrey V MatousDavid MacDonaldConstantine S TamOlivier TournilhacShuo MaSteven P TreonAlbert OriolJerry PingEva M BrisoIsrael Arango-HisijaraMeletios A DimopoulosPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
In the final analysis from iNNOVATE, single-agent ibrutinib continued to show sustained efficacy in patients with heavily pretreated, rituximab-refractory Waldenström macroglobulinemia.